Condition
Triple Negative Breast Cancer (TNBC), Early Setting
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Not Yet Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07551765Not Yet RecruitingPrimary
Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and Immunotherapy.
NCT06831955Phase 2RecruitingPrimary
LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer
NCT07486687Phase 3Not Yet RecruitingPrimary
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
Showing all 3 trials